A Pharmacokinetic Study of Abiraterone Acetate in Male Participants With Impaired Renal Function Compared to Individuals With Normal Renal Function

NCT ID: NCT01715259

Last Updated: 2012-11-19

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 16 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-08-31
• Study Completion Date: 2010-01-31

Brief Summary

The purpose of this study is to determine the pharmacokinetic (how the drug concentrations change over time) profile of abiraterone acetate 1000 mg when administered as a single dose in male participants with impaired renal function compared to individuals with normal renal function.

Detailed Description

This is an open-label (identity of assigned study drug will be known) pharmacokinetics study evaluating a single dose of abiraterone acetate 1000 mg administered in male participants with end-stage renal disease compared to matched-control (matched for age and body mass index) participants with normal renal function. There will be approximately 8 participants in each cohort (group). The total study duration for each participant will be 36 days. Abiraterone acetate 1000 mg will be administered orally (by mouth) as a single dose in the fasted state on Day 1. No food will be ingested for 4 hours post-dose. Participants will be confined to the clinical research center from the day prior to dosing (Day -1) to Day 5 and will return to the clinic on Days 8, 15, and 22 for follow up. Serial pharmacokinetic samples will be collected and safety will be monitored throughout the study.

Conditions

Renal Insufficiency

Keywords

Renal insufficiency; Renal impairment; End-stage renal disease; Abiraterone acetate; Pharmacokinetics

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Abiraterone acetate

Group Type: EXPERIMENTAL

Abiraterone acetate: participants with end-stage renal disease

Intervention Type: DRUG

abiraterone acetate 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose in the fasted state on Day 1

Abiraterone acetate: matched control participants with normal renal function

Intervention Type: DRUG

abiraterone acetate 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose in the fasted state on Day 1

Interventions

Abiraterone acetate: participants with end-stage renal disease

abiraterone acetate 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose in the fasted state on Day 1

Intervention Type: DRUG

Abiraterone acetate: matched control participants with normal renal function

abiraterone acetate 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose in the fasted state on Day 1

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

All participants:

• Non-smokers or light smokers
• Body Mass Index of 18-38 kg/m2 inclusive
• Negative drug test, at screening and Day -1, for breathalyzer alcohol and drugs of abuse
• Negative HIV antibody test at screening
• Clinical laboratory values within protocol-defined parameters
• Agrees to protocol-defined use of effective contraception
• Participants may have concurrent stable medical conditions and may be included if the deemed condition(s) will not introduce an additional risk factor and will not interfere with the study objectives and procedures

Patients with renal impairment must additionally meet the following criteria:

• Must have protocol-defined criteria of end-stage renal disease, moderate or mild renal impairment
• Evidence of stable renal impairment

Control participants with normal renal function must additionally meet the following criteria:

• Must be in good health

Exclusion Criteria

All participants:

• Medical history of malignancy except non-melanoma skin cancer
• Participation in any other investigational study drug trial in which receipt of an investigational study drug occurred within 5 half-lives of that drug or 30 days prior to dosing with abiraterone acetate, whichever is longer
• History of alcoholism or drug abuse within the past 12 months
• Significant history or clinical manifestation as determined by the Investigator of any significant metabolic, allergic, dermatological, hepatic, hematological, pulmonary, cardiovascular, immunologic, neurological, psychiatric or gastrointestinal conditions, surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs
• Clinically significant arrhythmias and/or history or presence of a clinically significantly abnormal electrocardiogram
• Acute illness, especially any active and uncontrolled infection
• Not willing to refrain from strenuous exercise from 48-hours prior to Day -1 and during the period of confinement at the clinical site
• Not willing to abstain from consuming: grapefruit- or caffeine-containing foods or beverages for 72 hours prior to Day -1 and alcohol-containing foods or beverages for 24 hours prior to Day -1
• Donation of blood or significant loss of blood within 56 days prior to Day 1 or planned donation of blood or plasma from screening through 30 days after Day 1, inclusive
• The use of any prescription or over-the-counter (OTC) preparation known to significantly inhibit or induce liver enzymes involved in drug metabolism within 30 days prior to Day 1
• Use of any prescription medications/products or any OTC, non-prescription preparations unrelated to existing allowable stable medical conditions within 5 half-lives of that product or 7 days prior to dosing with abiraterone acetate, whichever is longer
• Any acute or chronic condition that, in the opinion of the Investigator, would limit the individual's ability to complete and/or participate in this clinical study

Patients with renal impairment who meet any of the following criteria will be excluded from the study:

• Acute or exacerbating renal disease, fluctuating or rapidly deteriorating renal function as indicated by widely varying or worsening of signs of renal impairment within 2 weeks of Day 1
• Hypertension (systolic blood pressure [BP] >180 or diastolic BP >100)

Control participants with normal renal function who meet any of the following criteria will be excluded from the study:

• Hypertension (systolic BP >=160 or diastolic BP >=95)
• Any significant laboratory results consistent with renal impairment

• Minimum Eligible Age: 40 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

Cougar Biotechnology, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Cougar Biotechnology, Inc. Clinical Trial

Role: STUDY_DIRECTOR

Cougar Biotechnology, Inc.

Locations

Orlando, Florida, United States

Countries

United States

References

Marbury T, Lawitz E, Stonerock R, Gonzalez M, Jiao J, Breeding J, Haqq C, Verboven P, Stieltjes H, Yu M, Molina A, Acharya M, Chien C, Tran N. Single-dose pharmacokinetic studies of abiraterone acetate in men with hepatic or renal impairment. J Clin Pharmacol. 2014 Jul;54(7):732-41. doi: 10.1002/jcph.253. Epub 2014 Jan 17.

Reference Type: DERIVED

PMID: 24374856 (View on PubMed)

Other Identifiers

COU-AA-012

Identifier Type: OTHER

Identifier Source: secondary_id

CR016951

Identifier Type: -

Identifier Source: org_study_id